Ratings Oculis Holding AG

Equities

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
12.07 ^USD	+0.88%		-5.70%	+7.48%

May. 08	Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	MT

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	ESG Refinitiv
OCULIS HOLDING AG	+7.48%	503M	-
MODERNA, INC.	+17.96%	44.96B	B-
IQVIA HOLDINGS INC.	+1.17%	42.65B	B
LONZA GROUP AG	+48.77%	41.85B	A
CELLTRION, INC.	-4.27%	29.04B	C
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B	B
BIO-TECHNE CORPORATION	+4.86%	12.75B	B+
MEDPACE HOLDINGS, INC.	+27.29%	12.06B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality